头孢他啶用于急性髓系白血病伴发热性中性粒细胞减少症患者：持续静脉输注在最大化药效学暴露方面的作用
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
作者信息
Pea Federico, Viale Pierluigi, Damiani Daniela, Pavan Federica, Cristini Francesco, Fanin Renato, Furlanut Mario
机构信息
Institute of Clinical Pharmacology and Toxicology, DPMSC, University of Udine, P. le S. Maria della Misericordia 3, 33100 Udine, Italy.
出版信息
Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3. doi: 10.1128/AAC.49.8.3550-3553.2005.
Abstract
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.
摘要
对20例患有急性髓系白血病的发热性中性粒细胞减少患者，评估了每日6克头孢他啶持续静脉输注的药代动力学-药效学特征。从第2天起，头孢他啶的平均稳态浓度为40毫克/升，确保了最大的药效学暴露（该值接近针对铜绿假单胞菌的最低抑菌浓度断点的四到五倍）。然而，在整个研究期间记录到了较大的个体内和个体间药代动力学变异性。
相似文献
1
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.头孢他啶用于急性髓系白血病伴发热性中性粒细胞减少症患者：持续静脉输注在最大化药效学暴露方面的作用
Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3. doi: 10.1128/AAC.49.8.3550-3553.2005.
2
Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.发热中性粒细胞减少症行 HSCT 儿童中头孢他啶持续输注的群体药代动力学：对铜绿假单胞菌经验性治疗达标率的影响。
J Antimicrob Chemother. 2019 Jun 1;74(6):1648-1655. doi: 10.1093/jac/dkz065.
3
Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.
Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):188-92. doi: 10.1007/BF02310354.
4
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.对于使用头孢他啶连续输注与间歇输注来对抗铜绿假单胞菌，是否存在药效学需求？一个体外药效学模型。
J Antimicrob Chemother. 2005 Feb;55(2):209-13. doi: 10.1093/jac/dkh536. Epub 2005 Jan 13.
5
6
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.囊性纤维化患者和健康志愿者中头孢他啶的群体药代动力学比较和药效学折点。
Antimicrob Agents Chemother. 2010 Mar;54(3):1275-82. doi: 10.1128/AAC.00936-09. Epub 2010 Jan 11.
7
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.在体外感染模型中，头孢他啶单独持续输注或间歇推注以及与每日单次剂量阿米卡星联合应用对铜绿假单胞菌的药效学研究。
Antimicrob Agents Chemother. 1995 Aug;39(8):1797-801. doi: 10.1128/AAC.39.8.1797.
8
In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.在铜绿假单胞菌肺炎实验模型中，人源化间歇给药与持续给药的头孢他啶联合妥布霉素的体内疗效。
Int J Antimicrob Agents. 2008 Dec;32(6):494-8. doi: 10.1016/j.ijantimicag.2008.07.010. Epub 2008 Sep 18.
9
Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.持续给予针对PBP-2和PBP-3的β-内酰胺类药物会在小鼠铜绿假单胞菌和大肠杆菌败血症中引发更高的细胞因子反应。
J Antimicrob Chemother. 2007 May;59(5):926-33. doi: 10.1093/jac/dkm073. Epub 2007 Mar 29.
10
Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer.
J Pediatr Hematol Oncol. 2002 Dec;24(9):714-6. doi: 10.1097/00043426-200212000-00006.
引用本文的文献
1
Predictors of mortality and progression from colonization to Stenotrophomonas maltophilia bloodstream infection in hematologic disorders: a single-center retrospective study.血液系统疾病中死亡率及从嗜麦芽窄食单胞菌定植进展为血流感染的预测因素：一项单中心回顾性研究
Eur J Clin Microbiol Infect Dis. 2025 Jul 25. doi: 10.1007/s10096-025-05217-2.
2
The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.荷兰抗生素政策工作小组（SWAB）关于癌症患者发热性中性粒细胞减少症诊断与管理的建议
Infect Dis Ther. 2022 Dec;11(6):2063-2098. doi: 10.1007/s40121-022-00700-1. Epub 2022 Oct 14.
3
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.在抗菌药物耐药时代理解和管理癌症患者的脓毒症
Front Med (Lausanne). 2021 Mar 31;8:636547. doi: 10.3389/fmed.2021.636547. eCollection 2021.
4
Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and .持续输注美罗培南在血液系统恶性肿瘤伴发热性中性粒细胞减少患者中的群体药代动力学：针对肠杆菌科细菌优化经验性治疗的给药策略及…… （原文结尾不完整）
Pharmaceutics. 2020 Aug 19;12(9):785. doi: 10.3390/pharmaceutics12090785.
5
Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study.基于实时治疗药物监测的美罗培南持续输注优化用于改善肿瘤血液病患者中性粒细胞减少性发热的治疗结局：一项前瞻性、单中心、干预性研究的结果。
J Antimicrob Chemother. 2020 Oct 1;75(10):3029-3037. doi: 10.1093/jac/dkaa267.
6
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).β-内酰胺类抗生素延长输注治疗血液系统肿瘤患者发热性中性粒细胞减少症的疗效：一项随机、多中心、开放标签、优效性临床试验方案（BEATLE）。
Trials. 2020 May 18;21(1):412. doi: 10.1186/s13063-020-04323-0.
7
Antibiotic therapy in hematological neutropenic patients: what is the news?血液学中性粒细胞减少患者的抗生素治疗：有什么新进展？
Leuk Suppl. 2012 Aug;1(Suppl 2):S20-1. doi: 10.1038/leusup.2012.13. Epub 2012 Aug 9.
8
Vancomycin dosing in neutropenic patients.中性粒细胞减少患者的万古霉素给药剂量。
PLoS One. 2014 Nov 12;9(11):e112008. doi: 10.1371/journal.pone.0112008. eCollection 2014.
9
Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.血液系统恶性肿瘤伴发热性中性粒细胞减少患者哌拉西林的药代动力学改变。
Antimicrob Agents Chemother. 2014 Jun;58(6):3533-7. doi: 10.1128/AAC.02340-14. Epub 2014 Mar 31.
10
The prevention and management of infections due to multidrug resistant organisms in haematology patients.血液学患者中多重耐药菌感染的预防与管理
Br J Clin Pharmacol. 2015 Feb;79(2):195-207. doi: 10.1111/bcp.12310.
本文引用的文献
1
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.重症患者的抗菌治疗：对导致药物处置改变和药代动力学变异性的病理生理状况的综述。
Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002.
2
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.对于使用头孢他啶连续输注与间歇输注来对抗铜绿假单胞菌，是否存在药效学需求？一个体外药效学模型。
J Antimicrob Chemother. 2005 Feb;55(2):209-13. doi: 10.1093/jac/dkh536. Epub 2005 Jan 13.
3
Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.替考拉宁用于急性白血病合并发热性中性粒细胞减少症患者：受益于更高剂量的特殊人群。
Clin Pharmacokinet. 2004;43(6):405-15. doi: 10.2165/00003088-200443060-00004.
4
Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis.住院恶性血液病患者的菌血症：一项在无抗菌药物预防措施的14年期间对病原体及其耐药谱的回顾性研究。
Hematol J. 2003;4(6):420-6. doi: 10.1038/sj.thj.6200334.
5
Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center.
Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):137-43. doi: 10.1007/s10096-003-0894-6. Epub 2003 Mar 5.
6
Treatment of febrile neutropenia: what is new?发热性中性粒细胞减少症的治疗：有哪些新进展？
Curr Opin Infect Dis. 2002 Aug;15(4):377-82. doi: 10.1097/00001432-200208000-00004.
7
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.2002年癌症中性粒细胞减少患者抗菌药物使用指南。
Clin Infect Dis. 2002 Mar 15;34(6):730-51. doi: 10.1086/339215. Epub 2002 Feb 13.
8
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.对重症监护患者持续输注头孢他啶的稳定性和相容性
Antimicrob Agents Chemother. 2001 Sep;45(9):2643-7. doi: 10.1128/AAC.45.9.2643-2647.2001.
9
Pharmacokinetics of ceftazidime in febrile neutropenic patients.
Scand J Infect Dis. 2001;33(3):222-6. doi: 10.1080/00365540151060941.
10
Population pharmacokinetics of amikacin in patients with haematological malignancies.阿米卡星在血液系统恶性肿瘤患者中的群体药代动力学。
J Antimicrob Chemother. 1999 Aug;44(2):235-42. doi: 10.1093/jac/44.2.235.
Zotero 插件